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Based on recent findings, an increased late sodium current (INa,late) plays an important
pathophysiological role in cardiac diseases, including rhythm disorders. The article first
describes what is INa,late and how it functions under physiological circumstances. Next, it
shows the wide range of cellular mechanisms that can contribute to an increased INa,late in
heart diseases, and also discusses how the upregulated INa,late can play a role in the
generation of cardiac arrhythmias. The last part of the article is about INa,late inhibiting
drugs as potential antiarrhythmic agents, based on experimental and preclinical data as
well as in the light of clinical trials.
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channel inhibitorsINTRODUCTION
During the non-pacemaker action potential (AP) in the heart, depolarization of the cell membrane
opens voltage gated sodium channels (Nav) for a short period of time (Scanley et al., 1990; Mitsuiye
and Noma, 2002) giving rise to the early sodium current peak (INa,early). This INa,early causes the
upstroke of the non-pacemaker AP. Through the course of the AP Nav channels may recover from
inactivation and reopen, generating a sustained current component, called late sodium current
(INa,late). INa,late flows throughout the plateau phase of the AP therefore it significantly contributes to
AP morphology, even though its magnitude is only a fraction of INa,early (Figure 1A).
If INa,late is increased, it might play a pathophysiological role in acquired cardiac diseases (Figure 1B)
such as myocardial ischemia (Maier and Sossalla, 2013) and heart failure (Coppini et al., 2013; Pourrier
et al., 2014). In the cardiomyocytes, an upregulated INa,late hinders repolarization and causes a larger
sodium entry, therefore increasing intracellular sodium concentration ([Na+]i). An increased [Na
+]i, in
turn, leads to a larger intracellular calcium content. These factors together can possibly cause contractile
dysfunction (Sossalla et al., 2011), disturbed myocardial energetics (Liu and O'Rourke, 2008) and
cardiac arrhythmias (Antzelevitch et al., 2014).ELECTROPHYSIOLOGICAL IDENTIFICATION OF INA,LATE
Mammalian cardiac cells express a wide variety of Nav isoforms, differing in unit conductance,
voltage sensitivity, kinetics, and drug sensitivity. In the majority of cardiac tissues, the dominant
isoform of the pore-forming subunit is Nav1.5, which is relatively insensitive to the sodium channelin.org April 2020 | Volume 11 | Article 4131
Horváth et al. Antiarrhythmic Late Sodium Current Inhibitiontoxin tetrodotoxin (TTX) (Gellens et al., 1992; Catterall et al.,
2005). Many of the TTX-sensitive (“non-cardiac”) Nav channels
(Nav1.1, Nav1.2, Nav1.3, Nav1.4, and Nav1.6) are also shown to be
present in cardiac tissue (Maier et al., 2002; Haufe et al., 2005;
Valdivia et al., 2005; Biet et al., 2012; Yang et al., 2012). In nodal
tissue Nav1.1 and Nav1.6 are expressed in the largest quantities.
Besides the pore-forming subunit, four auxiliary subunits (ß1, ß2,
ß3, and ß4) and certain scaffolding proteins also participate in
building up the whole complex, which also attaches to the
cytoskeleton. These molecules can interact with each other and
may modify the kinetics and voltage dependence of the actual
channel (Malhotra et al., 2001).
Mechanisms that are discussed in the followings may
contribute to the profi le of INa , l a te during the AP.
Understanding these mechanisms better might be helpful in
developing new antiarrhythmic therapeutic strategies targeting
INa,late.
INa,late Is Underlain by Different Channel
Gating Modes
At the resting membrane potential, the vast majority of Nav1.5
channels are in their closed state. Upon depolarization, Nav1.5
channels open up within 1–2 ms after which they inactivate
rapidly (Scanley et al., 1990; Mitsuiye and Noma, 2002). This
produces INa,early and the upstroke of the non-pacemaker cardiac
AP. During a sustained depolarization, Nav1.5 channels can
reopen with a small probability. In ventricular myocytes, three
modes of Nav1.5 channel activity have been characterized in
single-channel experiments: transient mode (TM), burst mode
(BM), and late scattered mode (LSM) (Maltsev, 2006).
INa,early is mainly the result of TM activity, while BM and LSM
are responsible for the sustained sodium current, INa,late (Figure
1A). The magnitude of the sustained current component is only
about 0.5–1 % of INa,early measured 50 ms after the onset of the
depolarizing pulse (Maltsev, 2006). During a sustainedFrontiers in Pharmacology | www.frontiersin.org 2depolarization BM openings rapidly decline in the first tens of
milliseconds therefore leaving LSM as the gating mode being
mainly responsible for INa,late toward the end of the
plateau phase.
Mutations of the channel protein and certain diseases can
change the contribution of different Nav1.5 channel activity
patterns to the macroscopic current, therefore increasing INa,late
(Bezzina et al., 1999; Valdivia et al., 2005; Wu et al., 2006;
Maltsev et al., 2007; Maltsev and Undrovinas, 2008; Song et al.,
2008; Maltsev et al., 2009; Xi et al., 2009; Guo et al., 2010; Trenor
et al., 2012) (Figure 1B). Apparently, each gating mode has a
distinct drug sensitivity or drug affinity as well (Belardinelli et al.,
2004; Ravens et al., 2004; Belardinelli et al., 2006). Based on this,
selective pharmacological targeting of certain gating modes
might have potential antiarrhythmic and/or cardioprotective
effects (Belardinelli et al., 2006; Hoyer et al., 2011; Morita
et al., 2011).
Window Sodium Current
The voltage dependence of the steady state activation and
inactivation of most Nav channels overlaps with each other (Zaza
and Rocchetti, 2013). This overlap provides a voltage range
(“window”) where inactivated Nav channels are able to recover
from inactivation and then might reopen. When the actual
membrane potential falls within this “window” of overlap, a
sustained current is evoked. Under physiological circumstances
this “window current” mechanism likely plays a limited role in
INa,late, because the Nav1.5 voltage “window” is around −70 mV,
falling quite far from the AP plateau. Additionally, in the window
voltage range, the current density is less than 5 % of the maximum
current density in healthy myocytes (Maltsev et al., 1998; Wang
et al., 2002; Liu et al., 2007). Hence, the “window current”
mechanism is unlikely to be a major determinant of INa,late in
healthy myocytes. Mutations of channel proteins or altered
regulation in certain diseases may shift either the steady-stateA B
FIGURE 1 | The early and the late component of the sodium current under physiological (A) and pathological (B) conditions. Upper panels: membrane potential;
lower panels: sodium current. INa,early, early (peak) component of the sodium current; INa,late, late (sustained) component of the sodium current.April 2020 | Volume 11 | Article 413
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change this voltage window, therefore increasing INa,late under these
pathological conditions (Wang et al., 1996; Ruan et al., 2009).
Non-Equilibrium Channel Gating
During the AP of cardiac myocytes, the membrane potential changes
continuously. Nav channels are incorporated into this dynamic
system. It has been proposed by Clancy et al. (2003) that the
voltage “history” of the cell membrane can modulate the transition
between Nav channel states, termed “non-equilibrium gating”. As a
result, recovery from inactivation is also modulated by the dynamics
of voltage change. The theory is supported by experimental data
showing that the application of repolarizing voltage ramps or AP
shape voltage commands evoke a larger INa,late compared to
conventional square pulses or model simulations where “non-
equilibrium gating” is not incorporated into the numerical model
(Clancy et al., 2003; Magyar et al., 2004; Horvath et al., 2013).
Non-Cardiac Sodium Channel Isoforms in
the Heart
Epilepsy (Alekov et al., 2000; Akalin et al., 2003) and certain skeletal
muscle diseases (Komajda et al., 1980; Pereon et al., 2003) has been
associated with pathological ECG recordings. Therefore it seemed
possible that non-cardiac sodium channel mutations might cause
electrical alterations in the heart. Later, Nav1.1, Nav1.2, Nav1.3,
Nav1.4, Nav1.6, and Nav1.8 isoforms have been identified in cardiac
tissue (Maier et al., 2002; Haufe et al., 2005; Valdivia et al., 2005; Biet
et al., 2012; Yang et al., 2012). Based on the findings of Biet et al., as
much as 44 % of INa,late is due to non-cardiac sodium channels (Biet
et al., 2012) in canine ventricular cardiomyocytes. Furthermore,
Yang et al. have shown that in mice and rabbit the TTX-resistant
Nav1.8 provides a substantial amount of INa,late (Yang et al., 2012).
Based on these experimental data, isoform specific sodium channel
modulators might provide a valid approach in pharmacological
antiarrhythmic therapy (See Non-Cardiac Sodium Channel
Inhibitors as Potential Antiarrhythmic Agent for further details).ROLE OF INA,LATE IN CARDIAC
PHYSIOLOGY
Role of INa,late in Cardiac Electrical Activity
Contribution of INa,late to cardiac APs was questioned because
of its small density. However, the plateau phase of the cardiac
AP is shaped by a delicate balance between minuscule inward
and outward current fluxes. Therefore even a small change in
these currents may significantly alter the duration of the AP
(Horvath et al., 2006). Inhibition of INa,late substantially
shortens the cardiac AP in the conductive system
(Coraboeuf et al., 1979) and in ventricular cells (Kiyosue
and Arita, 1989) as well, indicating that INa,late significantly
contributes to determining the duration of the non-
pacemaker AP in cardiac myocytes. Recent AP voltage
clamp experiments show that the density of INa,late is of
similar magnitude as the major potassium currents in
g u i n e a p i g (Ho r v a t h e t a l . , 2 0 1 3 ) a n d r a b b i tFrontiers in Pharmacology | www.frontiersin.org 3(Hegyi et al., 2018) ventricular myocytes. There is a
characteristic interspecies difference in the shape of INa,late
as shown in the case of guinea pig, canine, and human
ventricular myocytes (Horvath et al., 2020).
The sustained sodium current is also an important factor in
determining electrophysiological properties of sinoatrial node
cells (Maier et al., 2003; Lei et al., 2004). Tetrodotoxin, applied in
lower than 1 µM concentrations, reduces the rate of spontaneous
depolarization in sinoatrial node cells (Huang et al., 2015),
clearly indicating that non-cardiac Nav isoforms also
contribute to cardiac automaticity.
Cardiac Purkinje cells have the largest rate-dependence of
their AP duration (APD) among cardiomyocytes with fast
response APs. Purkinje cell APs are longer at lower stimulation
rates, while shorter at higher rates than APs of ventricular cells. It
has been shown that INa,late contributes to this feature by
possessing much slower decay and recovery kinetics in
Purkinje cells than in ventricular cells. As a result Purkinje cell
INa,late is significantly larger at low heart rates, while smaller at
high heart rates compared to ventricular cells. This unique
feature predisposes Purkinje cells to serve as triggers in
generating arrhythmias (Li et al., 2017).
INa,late plays a role in forming the atrial AP as well
(Burashnikov and Antzelevitch, 2013; Luo et al., 2014). INa,late
is expected to be larger in atria than in ventricles because INa, early
density is greater in atrial cells under similar conditions (Li et al.,
2002; Burashnikov et al., 2007), suggesting a higher sodium
channel expression in atrial cells. On the other hand, an
overall more positive membrane potential, and a more negative
steady-state inactivation voltage of the sodium current (Li et al.,
2002; Burashnikov et al., 2007) in the atrial cells reduce the
availability of the sodium channels (Burashnikov and
Antzelevitch, 2008). In one set of experiments by Luo et al.
maximum INa,late density has been reported to be greater in
rabbit left atrial myocytes than in ventricular cells (Luo et al.,
2014) and in a different investigation the two cell types seemed to
be similar in this matter (Persson et al., 2007). APs are shorter in
the atria compared to the ventricles reducing the amount of Na+
influx through INa,late in the former (Burashnikov and
Antzelevitch, 2013).
INa,late Plays a Significant Role in the
Sodium Homeostasis of Cardiomyocytes
[Na+]i is set by a dynamic equilibrium of the influx of Na
+ into
the cell and efflux of Na+ to the interstitial space. The [Na+]i of
non-paced ventricular myocytes is around 4–8 mM in guinea-
pig, rabbit, and canine; and about twice as high in rat and mouse
(9–14 mM) (Despa and Bers, 2013). In non-paced human
myocytes [Na+]i is thought to be in the 4–10 mM range.
Na+ can enter into the cell through Na+ channels, Na+/Ca2+
exchanger (NCX) and Na+/H+ exchanger (NHE). Na+ leaves the
cell mainly via the Na+/K+ pump (NKP), but the reverse mode
NCX is also responsible for a moderate Na+ efflux during the first
few milliseconds of the cardiac AP. Furthermore, Na+/HCO3
−
cotransport, Na+/Mg2+ exchange, and Na+/K+/2Cl− cotransport
can play a role in the sodium homeostasis of cardiomyocytes to aApril 2020 | Volume 11 | Article 413
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that Na+ concentrations between the cytosol and intracellular
organelles are continuously balanced.
Upon pacing, [Na+]i increases with increasing stimulation
frequency, caused by the larger Na+ entry through Na+ channels
and NCX. In paced, single cardiac cells approximately 25 % of
the Na+ entry is mediated by Nav channels (Despa and Bers,
2013). The Na+ entry through Nav channels is about equally
distributed between INa,early and INa,late (Makielski and Farley,
2006; Zaza and Rocchetti, 2013; Despa and Bers, 2013; Shryock
et al., 2013), however this contribution can change at different
heart rates (seeHeart Rate and AP Duration Influences INa,late for
details). The higher Na+ influx into paced cells is matched by an
increased efflux through an elevated NKP activity. This is mainly
caused by the increased [Na+]i itself, but nitric oxide-, and
phospholemman-dependent mechanisms can also add to this
effect (Despa and Bers, 2013).
Na+ and Ca2+ Homeostasis Is Linked in
Cardiomyocytes
The Direct Connection Between Na+ and Ca2+
Homeostasis: Na+/Ca2+ Exchanger
The NCX is a secondarily active transporter that carries 1 Ca2+
and 3 Na+ at the same time (Janvier and Boyett, 1996; Fujioka
et al., 2000; Sipido et al., 2007; Despa and Bers, 2013; Ginsburg
et al., 2013). The NCX function is determined by the relation of
the actual membrane voltage and the sum of the actual
electrochemical gradients of Ca2+ and Na+. The main role of
NCX is to remove Ca2+ from the cells by utilizing the potential
energy present in the form of Na+ gradient (“forward mode”).
Besides this mode, in the first few milliseconds of the AP, NCX
mediates Na+ extrusion from the cell and Ca2+ entry into the
cytosol (“reverse mode”).
INa,late Facilitates Ca
2+ Influx via L-Type Calcium
Channels
Being an inward current, INa,late depolarizes the membrane,
causing an increased membrane potential throughout the
plateau phase and a longer AP. The more time the membrane
spends in a depolarized state (above +40 mV) the higher the
possibility that L-type calcium channels can open or re-open. It is
well documented with AP voltage clamp technique that the L-
type calcium current is flowing throughout the AP plateau (Linz
and Meyer, 1998; Linz and Meyer, 2000; Banyasz et al., 2003;
Fulop et al., 2004; Banyasz et al., 2012). Therefore a longer AP
inevitably results in a larger Ca2+ entry to the myocyte.
Heart Rate and AP Duration
Influences INa,late
Heart rate determines the magnitude of INa,late. Like many
electrophysiological characteristics of cardiac cells (Banyasz
et al., 2009), INa,late is reverse-rate dependent, so the faster the
stimulation rate the smaller the current density will be
(Nagatomo et al., 2002; Wu et al., 2011). However, with
increasing heart rate the density of INa,early and maximum rate
of depolarization during the AP upstroke (Vmax; an APFrontiers in Pharmacology | www.frontiersin.org 4parameter determined by INa,early) does not decrease that much
(Nagatomo et al., 2002). This is because recovery of INa,late is
much slower than INa,early (Carmeliet, 2006). At higher heart
rates this feature of the two sodium current components also
results in a decreasing contribution of INa,late to the overall Na
+
influx. Under these conditions, the more frequent AP upstrokes
cause a greater Na+ entry through INa,early, and there is a
reduction of INa,late density because of the very slow INa,late
recovery kinetics. Moreover, rate-dependent changes of the AP
length also influence Na+ entry. At high heart rates APs are
shorter, therefore INa,late is active for a shorter time, accounting
for a further reduction of Na+ influx through the already smaller
INa,late. At the same time, extrusion of Na
+ by the NKP is reduced
at high pacing rates (Despa and Bers, 2013) leading to a rate-
dependent [Na+]i loading in isolated cells. It must also be noted
that this phenomenon is largely offset or may not occur at all
during b-adrenergic stimulation because it augments NKP
activity through phospholemman (Cheung et al., 2010).).
As it is described in the previous section, APD influences
INa,late: the shorter the AP the smaller the Na
+
flux through INa,late
is. Therefore under any conditions that result in a shorter AP the
contribution of INa,late to the overall Na
+ influx will be smaller.
This fact, together with significant differences in heart rate
underlies differences in INa,late between species having short
APs (e.g.: rats or mice) and long APs (guinea pig, rabbit, pig,
human, etc.). In rats and mice both INa,late and Na
+ influx driven
by INa,late should be much smaller than in species having
long APs.
Modulation of INa,late
Cytosolic Ca2+ Modulates INa,late in a Complex Way
Ca2+ is the key player in the excitation-contraction coupling of
cardiac cells and it also regulates many other cellular functions
including sarcolemmal transport mechanisms. Nav channels are
regulated by the individual and cooperative actions of Ca2+,
calmodulin (CaM), and Ca2+-CaM dependent protein kinase II
(CaMKII) as well (Bers and Grandi, 2009; Maier, 2011; Scheuer,
2011). Signaling through the Ca2+—CaM—CaMKII pathway is
thought to facilitate the sodium current, especially INa,late
(Maltsev et al., 2008; Maltsev et al., 2009; Bers and Grandi, 2009).
Nav Channels, Ca
2+ and CaM
Motifs with Ca2+ binding (EF hand) as well as CaM binding (IQ
motifs) capabilities are present in the Nav1.5 channel structure.
Some groups have shown that Ca2+ alone can regulate sodium
channels (Wingo et al., 2004), while other results support that
Ca2+ is not capable of regulating Nav channels directly; the
regulation is mediated via Ca2+-CaM complex (Tan et al.,
2002; Kim et al., 2004). Besides the exact regulatory
mechanism, the general agreement is that when Ca2+ is
elevated the SSI curve shifts toward more positive voltages
(Sarhan et al., 2012), although this is a largely negligible effect
at physiologically relevant Ca2+ concentrations in wild type
channels. However, under conditions when Ca2+ or CaM
sensing regions are mutated or when the Ca2+ sensitivity of
Nav channels are severely altered, diverse functional disturbances
may arise leading to an increased INa,late.April 2020 | Volume 11 | Article 413
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Besides the direct regulation of Nav channels, the Ca
2+-CaM
complex activates CaMKIIdC that also modulates these channels
(Zhang and Brown, 2004; Anderson, 2005; Bers and Grandi,
2009). The active CaMKII is a Ser/Thr kinase that can
phosphorylate Nav1.5 channels on at least three amino acid
residues (Grandi and Herren, 2014). While there is an ongoing
debate about the exact role of these phosphorylation sites in
channel gating, all the studies agree on that activation of CaMKII
increases INa,late.Complex Modulation by b-Adrenergic Stimulation
In a meticulous set of AP voltage clamp experiments, Hegyi et al.
(Hegyi et al., 2018) showed how different downstream elements
of the b-adrenergic pathway regulate INa,late in rabbit ventricular
myocytes. Protein kinase A, CaMKII, Epac, nitrosylation, as well
as reactive oxygen species (ROS) contributed to the upregulation
of INa,late during different phases of the ventricular AP.Cellular Metabolites
ROS and H2O2 increase INa,late (Song et al., 2004; Song et al.,
2006; Sossalla et al., 2008). Some results suggest that CaMKII can
be involved in INa,late facilitation observed in the presence of
oxygen free radicals (Wagner et al., 2011), because ROS can also
activate CaMKII (Erickson et al., 2008). See (Wagner et al., 2013)
for a detailed review.
Acidosis also modulates Nav channels (Murphy et al., 2011;
Jones et al., 2011; Jones et al., 2013a; Jones et al., 2013b). Acidosis
caused a rightward shift in steady-state activation, but not in
steady-state inactivation in isolated canine ventricular myocytes
therefore reducing INa,late (Murphy et al., 2011).
Many studies have found that hypoxia increases INa,late (Ju
et al., 1996; Carmeliet, 1999; Harnmarstrom and Gage, 2002;
Wang et al., 2007; Shimoda and Polak, 2011; Tang et al., 2012).
Following a 15 minute hypoxic period, Wang et al. reported an
increased BM channel activity, a plausible explanation of the
increased INa,late.
Intermediary lipid metabolites shown to increase INa,late. Nav
channels treated with lysophosphatidylcholine exhibited a
sustained BM channel activity (Burnashev et al., 1991;
Undrovinas et al., 1992), while palmitoylcarnitine induced a
slowly inactivating sodium current (Wu and Corr, 1994).
According to more recent data, poly-unsaturated fatty acids
(docosahexaenoic acid and eicosapentaenoic acid) reduce both
INa,early and INa,late (Pignier et al., 2007). According to the
authors, the reduction is caused by a decreased overlap
between the steady-state activation and inactivation
voltage range.
Nitric oxide (NO) has been shown to enhance INa,late (Ahern
et al., 2000). The neural NO synthase (nNOS) belongs to the
huge macromolecular complex of Nav1.5, with caveolin-3 and
a1-syntrophin among some additional proteins (Cheng
et al., 2013).Frontiers in Pharmacology | www.frontiersin.org 5Other Mechanisms
Transcriptional Regulation
The possible promoter regions and their role in the regulation of
human SCN5A gene transcription has already been reported.
(Yang et al., 2004; van Stuijvenberg et al., 2010) Recent studies
have shown that the zinc-finger transcription factor, GATA4
(Tarradas et al., 2017), and the myocyte enhancing factor-2C
(MEF2C) enhances SCN5A transcription (Zhou et al., 2018).
However, most likely many other transcription factors are
involved in the transcriptional regulation of the SCN5A gene.
Glycosylation
Some amino acid motifs found in the Nav1.5 protein are subject
to N-glycosylation. Carbohydrates account for an about 5 % of
the total mass of Nav channels in the rat heart (Cohen and Levitt,
1993). The lack of channel glycosylation caused shifts toward
positive voltages in both steady state activation and inactivation
curves when naturally sialic-acid deficient channels were used
(Zhang et al., 1999), or when these carbohydrate residues were
removed by enzymatic treatment (Ufret-Vincenty et al., 2001)
Glycosylation also seem to be involved in channel trafficking
(Mercier et al., 2015; Cortada and Brugada, 2019)
Protein Kinase C
Upon protein kinase C activation, Na+ channels are internalized
from the plasma membrane (Hallaq et al., 2012). For the process,
both channel phosphorylation on S1503 and ROS are required
(Liu et al., 2017).
Phosphorylation on Tyrosine Residues
The “Fyn” tyrosine kinase phosphorylates Nav1.5 channels on
the Y1495 Tyr residue, located in the III–IV linker domain. This
tyrosine residue helps with anchoring Ca2+/CaM to the
inactivation gate of the channel (Sarhan and Van Petegem,
2009). When Fyn phosphorylates the channel on Y1495, it
increases the window voltage range by shifting the steady-state
inactivation toward more positive potentials (Ahern et al., 2005),
therefore resulting in an enhanced INa,late.
Arginine Methylation
There are three known arginine residues in Nav1.5 (R513, R526,
and R680), that are subject to methylation (Beltran-Alvarez et al.,
2011). These residues are found in the domain I and domain II
linker region. There are two known mutations of these arginines
(namely R526H and R680H) that cause Brugada (Kapplinger
et a l . , 2010) and LQT3 syndromes (Wang et a l . ,
2007), respectively.
Mechanosensitivity
Mechanical stimuli also affect channel gating in Nav1.5 channels.
Beyder et al. investigated this phenomenon both in an expression
system (Beyder et al., 2010) and in isolated mouse ventricular
cells (Beyder et al., 2012). The pressure ramp applied by the
authors caused a 235 % increase in LSM Nav1.5 channel
openings suggesting that INa,late is enhanced by mechanical
stress. Similar mechanical effects can modify certain signal
transduction mechanisms like nNOS and CaMKII (Jian et al.,
2014), which can, in turn, increase INa,late.April 2020 | Volume 11 | Article 413
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AND ELEVATED INA,LATE IN CARDIAC
ARRHYTHMIAS
The pathophysiology of cardiac arrhythmias is based on the
classical concept of “arrhythmic triad”; combination of a
proarrhythmic substrate, a trigger, and the modulating effect of
the autonomic nervous system (Merchant and Armoundas, 2012).
The exact combination depends on etiology, cardiac-, and
extracardiac comorbidities. Abnormal [Na+]i homeostasis can
play a role in creating an arrhythmia-prone substrate as well as in
generating a trigger for the rhythm disorder. The discussed
mechanisms are summarized on Figure 2.
[Na+]i Increases in Many Cardiac
Pathologies
Compared to non-failing myocytes, [Na+]i is about 2–6 mM
larger in myocytes from failing hearts (Pieske et al., 2002; Despa
et al., 2002; Schillinger et al., 2006; Louch et al., 2010). In a
pressure- and volume-overload rabbit HF model, Despa et al.
have found an increased TTX-sensitive Na+ influx (Despa et al.,
2002). Interestingly, this larger influx was present not only in
electrically stimulated myocytes, but in non-paced cells as well.
In paced cells the most plausible candidate of this increased
TTX-sensitive Na+ influx is INa,late. However, the underlying
mechanism of this influx is not yet understood completely in
resting myocytes.Frontiers in Pharmacology | www.frontiersin.org 6INa,late Can Contribute to the Elevated
[Na+]i
Many cardiac diseases are associated with an increased INa,late.
The list contains cardiac myocytes originating from end-stage
HF (Maltsev et al., 1998; Maltsev et al., 2007) and post-
myocardial infarction (Huang et al., 2001) preparations as well
as animal HF models (Valdivia et al., 2005; Maltsev et al., 2007).
The larger INa,late can be caused by several pathophysiologic
factors including oxidative stress (ROS (Song et al., 2006; Sossalla
et al., 2008) and NO (Ahern et al., 2000) mainly by S-
nitrosylation of the Nav1.5 channels (Cheng et al., 2013)),
hypoxia (Carmeliet, 1999; Tang et al., 2012), mechanical stress
(Beyder et al., 2012), and certain ischemic metabolites, for
example oxidized lipids (Burnashev et al., 1991). Looking at
gating modes in single Nav1.5 channels, enhanced INa,late is likely
underlain by an increased number of BM and LSM openings
(Undrovinas et al., 2002; Maltsev, 2006) in HF.
The Ca2+—CaM—CaMKII signal transduction pathway is
upregulated in HF (Bers, 2010), and this pathway has been
shown to increase INa,late (Tan et al., 2002; Wagner et al., 2006;
Ashpole et al., 2012; Ma et al., 2012). Oxidation activates CaMKII
(Wagner et al., 2011) and keeps it constitutively active. The
enhanced CaMKII-mediated Nav1.5 phosphorylation, therefore,
certainly takes part in increasing INa,late under oxidative stress.
Recent studies have found that Nav1.8 expression is significantly
up-regulated, while Nav1.5 is reduced in human left ventricular
hypertrophy (Ahmad et al., 2019) and HF (Dybkova et al., 2018).FIGURE 2 | How can an impaired sodium homeostasis of cardiac myocytes lead to arrhythmias? AP, action potential; NHE, Na+/H+ exchanger; [Na+]i, intracellular
sodium concentration; NCX, Na+/Ca2+ exchanger; [Ca2+]i, intracellular calcium concentration; SR, sarcoplasmic reticulum; CaMKII, calcium/calmodulin dependent
protein kinase II.April 2020 | Volume 11 | Article 413
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[Na+]i—[Ca
2+]i—CaMKII
When [Na+]i is elevated, it makes the NCX forward mode
energetically less favorable, therefore a smaller amount of Ca2+
will leave the cell through NCX. This causes an increased [Ca2+]i
load, and therefore further activates CaMKII, leading to
enhanced phosphorylation of CaMKII targets such as Nav1.5.
This, in turn, increases INa,late, which further elevates [Na
+]i
finally creating an arrhythmogenic vicious circle (Grandi and
Herren, 2014). By using genetic (LQT3 mutation) as well as
pharmacological (anemone toxin-II, ATX-II) approaches to
increase INa,late, and therefore achieve [Na
+]i loading, Yao et al.
described this feedback (Yao et al., 2011). These conditions lead
to the vicious circle described above, and as a result, arrhythmias
can be generated because of an increase in the CaMKII-
dependent phosphorylation of phospholamban and RyRs.
[Na+]i—Mitochondrial [Ca
2+]—Oxidative
Stress—CaMKII—INa,late—[Na
+]i Feedback
The mitochondrial NCX dynamically equilibrate concentrations
of Ca2+ and Na+ of the mitochondrion and the cytosol. Ca2+ in
the mitochondrion plays a role in determining the production of
ATP and ROS by regulating the expression of enzymes involved
in oxidative phosphorylation (Yang et al., 2014). If [Na+]i is
elevated, it will impair Ca2+ accumulation in the mitochondrion
at high pacing rates, leading to a decrease in NADH/NAD+ redox
potential. This increases H2O2 generation in the cells (Liu and
O'Rourke, 2008), causing oxidative stress and thereby directly
and indirectly (through CaMKII (Erickson et al., 2008))
activating INa,late. Finally, the process leads to a further increase
in [Na+]i (Wagner et al., 2011). This shows that, similar to an
elevated [Na+]i, CaMKII activation can be caused by and can also
lead to an increased ROS production.
Arrhythmogenic Consequences of an
Increased INa,late and [Na
+]i
Many inherited and acquired diseases can lead to a longer
ventricular repolarization, presented as long QT (LQT)
syndromes (El-Sherif et al., 2019; Locati et al., 2019). The
inherited LQT3 syndrome is caused by an increased INa,late
because of a mutant, much slower inactivating Nav1.5 channel.
Acquired LQTs include for example heart failure (Maltsev et al.,
1998; Maltsev et al., 2007; Coppini et al., 2013), myocardial
ischemia and post-infarction state (Huang et al., 2001; Rivera-
Fernandez et al., 2016), and type 2 diabetes mellitus (Ninkovic
et al., 2016).
Under physiological conditions there is a fine balance between
the inward and outward currents during the AP plateau. During the
plateau phase the impedance of the membrane is large, therefore
even a small change in the delicate balance can lead to a marked
change in AP duration. In this setting, the depolarizing drive caused
by an increased INa,late causes a longer AP (Studenik et al., 2001;
Horvath et al., 2013), as well as under a longer AP, INa,late will
generate a larger Na+ influx. Even in normal hearts, both APD and
INa,late is greater in Purkinje fibers and in “M” cells than in the rest ofFrontiers in Pharmacology | www.frontiersin.org 7the myocardium contributing to the physiological heterogeneity of
repolarization. LQT syndromes increase both the spatial
heterogeneity of repolarization (Maltsev et al., 2007) and the
temporal variability of repolarization (El-Sherif et al., 2019) and
therefore can present an arrhythmogenic substrate. This can be
further exaggerated by bradycardia, where the APs are already long,
and having larger heterogeneity (Szentandrassy et al., 2015). Cardiac
diseases can also provide the proarrhythmic substrate in the form of
temporal repolarization heterogeneity, “repolarization alternans”
(Bonatti et al., 2014; Justo et al., 2016) which phenomenon is
more pronounced in tachycardia.
The trigger is also highly rate-dependent. At low heart rates,
where the cardiac APs are already long even under physiological
conditions, an augmented INa,late can further prolong
repolarization therefore increasing the probability of early
afterdepolarizations (EADs), and the risk for (fatal) ventricular
arrhythmias (Wang et al., 1995; Wang et al., 1996; Makita et al.,
2002; Hedley et al., 2009; Cardona et al., 2010; Yamamura et al.,
2010; Lowe et al., 2012). Severe bradycardia together with an
enhanced INa,late and a long APD may also promote delayed
afterdepolarization (DAD)-mediated triggered activities (Song
et al., 2008; Coppini et al., 2013; Horvath et al., 2013). These
triggered activities seem to heavily depend on an increased [Ca2+]i.
As described previously, an increased [Na+]i offsets NCX,
decreasing Ca2+ removal from the cytosol (Bers, 2002; Nagy
et al., 2004; Despa and Bers, 2013). This elevates diastolic [Ca2+]i
and therefore increasing SR Ca2+ content; leading to
spontaneous Ca2+ release events from the Ca2+-overloaded SR
(Gyorke and Terentyev, 2008). This can generate DADs and
therefore possibly triggering arrhythmias. At high heart rates this
can further be aggravated by the two feedback loops involving
CaMKII, as described in the previous sections, resulting in an
enhanced CaMKII mediated phosphorylation of RyR2 therefore
increasing the probability of spontaneous SR Ca2+ release events.
It must be noted again that in vivo, there is no high heart rate
without b-adrenergic stimulation. Adrenergic stimulation on one
hand further activates CaMKII (Hegyi et al., 2018) but on the
other hand, it also reduces or even diminishes [Na+]i loading of
the cells by enhancing NKP activity (Cheung et al., 2010). This
makes the role of INa,late in DAD-mediated arrhythmias
occurring at high heart rates questionable.
In the diseased heart, however, rate-dependent properties of
INa,late and [Na+]i are quite poorly investigated. At high pacing
rates, INa,late decreases in LQT3 DKPQ mutant cells (Nagatomo
et al., 2002) and an increased [Na+]i load was reported in
hypertrophied feline cells (Mills et al., 2007) as well as in
human cardiomyocytes from failing hearts (Pieske et al., 2002).
Pharmacologically enhanced INa,late increases repolarization
heterogeneity in intact, isolated rabbit and guinea pig hearts
(Restivo et al., 2004; Milberg et al., 2005), as well as in canine left
ventricular wedge preparations giving rise to TdP (Shimizu and
Antzelevitch, 1999a; Shimizu and Antzelevitch, 1999b). ATX-II
also induces AF in a wide range of experimental conditions (Lu
et al., 2012; Liang et al., 2016). Many gain-of-function SCN5A
mutations (including LQT3) have been associated with atrial
fibrillation (AF) (Benito et al., 2008). Also, in cases of chronicApril 2020 | Volume 11 | Article 413
Horváth et al. Antiarrhythmic Late Sodium Current Inhibition(permanent) AF, larger INa,late was found (Sossalla et al., 2010;
Poulet et al., 2015). These data suggest that enhancement of
INa,late might play a role in generating or maintaining AF most
likely because of [Na+]i overload dependent Ca
2+ overload
(Nattel and Dobrev, 2012).INA,LATE AS AN ANTIARRHYTHMIC
THERAPEUTIC TARGET
Sodium Channel Inhibitors
Natural products of peptide and non-peptide structure can
inhibit sodium channels, although these compounds have
negligible therapeutical relevance. Clinically relevant small-
molecule sodium channel inhibitors include local anesthetics,
anticonvulsants, and antiarrhythmic agents such as lidocaine,
carbamazepine, phenytoin, lamotrigine, and mexiletine. These
small-molecule inhibitors all bind to the so-called “local
anesthetic site” of sodium channels where amino acid residues
are highly conserved among different Nav subtypes (de Lera Ruiz
and Kraus, 2015). Because of this, the “classic” Nav blockers are
not subtype specific, they inhibit all subtypes to a certain extent.
Also, these compounds somewhat inhibit both INa,early and
INa,late, usually having a higher inhibitory effect on INa,late.
Therefore most Nav blockers reduce excitability and impulse
propagation (parameters associated with INa,early) together with
the plateau sodium current (INa,late).
Selective INa,late Inhibitors
A few sodium channel blockers differ from the “classic”
inhibitors, because they inhibit INa,late more potently than INa,
early. The molecular mechanism of the preferential INa,late
inhibition is still not completely understood. Even though
ranolazine was used for most of the experimental and clinical
studies, other selective INa,late inhibitors also exist such as
lidocaine, GS-458967, GS-462808, F15845, and GS-6615
(eleclazine). The half-maximal inhibitory concentration (IC50)
values of these inhibitors for the late and the early sodium
current component are summarized in Table 1. For a moreFrontiers in Pharmacology | www.frontiersin.org 8thorough data summary on this, see Table 2 in the review of
Antzelevitch et al. (2014).
For lidocaine, IC50 values of around 25 and 300 µM were
determined for INa,late and INa,early, respectively (Antzelevitch
et al., 2014).
In case of ranolazine, the IC50 values are 17 µM for INa,late and
1,329 µM for INa,early in rabbit (Belardinelli et al., 2013), whereas
6 µM for INa,late (Antzelevitch et al., 2004; Undrovinas et al.,
2006) and 294 µM for INa,early (Undrovinas et al., 2006) in canine
ventricular myocytes.
GS-458967 was found to have an IC50 of 333 nM for INa,late
inhibition while exhibiting smaller than 15% block of INa,early at the
same concentration at 1 and 3 Hz pacing frequencies (Koltun et al.,
2016a) measured on Nav1.5 channels expressed in HEK-293 cells
with automated patch-clamp. In rabbit ventricular cardiomyocytes,
the IC50 was 130 nM for INa,late, and at 10 µM, GS-458967 caused an
approximately 7.5 % reduction in INa,early. (Belardinelli et al., 2013).
Unfortunately for the developer, GS-458967 had a high brain
penetration and a profound use dependent block on all the
various sodium channel isoforms, making the compound prone
for possible central nervous system side effects (Koltun et al., 2016a).
GS-462808 has an IC50 of 1.9 µM for INa,late inhibition while
blocking 10 % of INa,early at 10 µM and it is also more cardiac
isoform selective than GS-458967 blocking only 8 % of the
Nav1.1 peak current. The problem with GS-462808 is that it
caused liver lesions during the acute animal toxicity tests (Koltun
et al., 2016b).
For GS-6615 the IC50 values of 0.62 and 51 µM were reported
for INa,late and INa,early blockade, respectively, in manual patch-
clamp experiments, with practically no effect on Nav1.1 channels
(Zablocki et al., 2016).
F15845 has an IC50 of 3.25 µM for the inhibition of
veratridine-induced INa,late while blocking 23 % of INa,early at 10
µM (Vacher et al., 2009). Last experimental data about F15845
were published in 2010, where it prevented ischemia-induced
arrhythmias in rats (Pignier et al., 2010). Since then no new
results came out regarding this agent.
Selectivity of these specific INa,late inhibitors is usually voltage-
dependent, these blockers have very little effect on INa,early at
more negative (quite unphysiological, for example −120 mV)
holding potentials. As the holding potential gets closer to
physiological resting membrane potentials, the selectivity of
these compounds decrease, they start to inhibit INa,early more.
Also, most inhibitors block the sodium channels in a rate-
dependent (“use-dependent”) fashion; the blockers are more
effective at rapid than at slow heart rates. This is because most
inhibitors preferentially bind to the open and/or inactivated
channels rather than the closed channel. This effect is
especially strong in sodium channel blockers having fast
association and dissociation kinetics (Pless et al., 2011)
(Vaughan-Williams class Ib agents).
In case of 1 µM GS-458967 for example, INa,early did not
change in rabbit ventricular myocytes held at −120 mV at pacing
rates of 0.1, 1, or 3 Hz. When the holding potential was −80 mV,
however, 1 µM GS-458967 reduced INa,early by 48 ± 7%, 50 ± 7%,TABLE 1 | IC50 values of selective late sodium current inhibitors for the late and
the early sodium current component.
Compound IC50 for Reference
INa,late INa,early
Lidocaine 29 µM 367 µM Antzelevitch et al., 2014
Ranolazine 17 µM 1329 µM Belardinelli et al., 2013
6 µM 294 µM Undrovinas et al., 2006
GS-458967 333 nM <15 % block at 333 nM Koltun et al., 2016a
130 nM 7.5 % reduction at 10 µM Belardinelli et al., 2013
GS-462808 1.9 µM 10 % reduction at 10 µM Koltun et al., 2016b
GS-6615 0.62 µM 51 µM Zablocki et al., 2016
F15845 3.25 µM 23 % reduction at 10 µM Vacher et al., 2009Where the IC50 value is missing, inhibition percentage at a given concentration was used
instead.April 2020 | Volume 11 | Article 413
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et al., 2013).
Ranolazine also inhibits sodium channels in a voltage-, and use-
dependent fashion, moreover this blockade is also significantly larger
in atria compared to ventricles (Zygmunt et al., 2011). With 50 ms
long depolarizing pulses and 250 ms diastolic intervals (at 3.33 Hz),
the use-dependent block by ranolazine at −120 mV was 21 % in
ventricular, versus 32 % in atrial cells, whereas at −100 mV the block
was 47 % versus 56 %, respectively. This data suggest that the rate
dependency (use-dependency) is very pronounced in case of INa,early
inhibition, but much smaller with INa,late. Therefore, based on the
rate-dependent physiological (see Heart Rate and AP Duration
Influences INa,late) and pharmacological characteristics of INa, early
and INa,late, a quite selective inhibition of INa,late might be achieved at
slow heart rates and with long APs, but at fast rates, with short AP
duration, sodium channel blockers similarly inhibit both INa, early and
INa,late.
At therapeutical plasma concentrations, ranolazine inhibits
other ionic currents besides INa,late. This includes IKr
(approximately 40 % inhibition at 6 µM), and ICa,L (around 25 %
inhibition at 6 µM) (Antzelevitch et al., 2004). Consequently,
inhibiting INa,late and applying ranolazine are very far from being
identical concepts. When ranolazine is used to inhibit INa,late,
effects on other channels must not be forgotten. Besides the
previous features, ranolazine is also a weak b-adrenergic
antagonist (Letienne et al., 2001) and an inhibitor of fatty acid
oxidation (Chaitman, 2006), even though this latter effect only
becomes prominent at supratherapeutical plasma concentrations.
Non-Cardiac Sodium Channel Inhibitors as
Potential Antiarrhythmic Agents
Riluzole blocks TTX-sensitive sodium channels preferentially,
which are associated with damaged neurons (Song et al., 1997).
Riluzole also directly inhibits the kainate and NMDA receptors
(Debono et al., 1993) as well as potentiates GABAA receptors (He
et al., 2002). In anaesthetized pigs, myocardial damage and
arrhythmias induced by coronary occlusion has been reduced
by riluzole (Weiss et al., 2013). Riluzole has also been found to be
anti-ischemic and antiarrhythmic in a pig model of acute
myocardial infarction. (Weiss and Saint, 2010).
Targeting Nav1.8 with specific inhibitors might provide a
potential novel approach in the future in antiarrhythmic drug
therapy, because recent studies have found that Nav1.8
expression is significantly up-regulated in human left
ventricular hypertrophy (Ahmad et al., 2019) and HF
(Dybkova et al., 2018). By using Nav1.8-specific blockers
[either A-803467 (30 nM) or PF-01247324 (1 mM)] the
authors managed to reduce INa,late and APD in these
experiments. Other Nav1.8 specific inhibitors include funapide
and VX-150, however these compounds have not been tested in
relation to cardiac pathophysiology so far.
Experimental Pathophysiology Studies
Because of the pronounced use-dependent effect of specific
INa,late inhibitors, interpretation of experimental studies
conducted on rats and mice (having resting heart rates aroundFrontiers in Pharmacology | www.frontiersin.org 9400 bpm) are very difficult. Therefore this review will focus on
experimental data originating from larger mammalian species.
Late Sodium Current Inhibition and Ventricular
Arrhythmias
As it was demonstrated in the previous sections, INa,late has quite
different characteristics under different heart rates. Therefore it is
worthwhile to split the ventricular arrhythmia topic into two
subtopics accordingly.
Bradycardia and Long APs
Many in vitro experimental studies have shown that at low
pacing rates with prolonged APs and increased repolarization
heterogeneity (LQT3 syndrome, heart failure, hypertrophic
cardiomyopathy), inhibition of INa,late effectively reduces the
burden of arrhythmic episodes [EADs, DADs, triggered APs,
Torsade de Pointes (TdP) (Shimizu and Antzelevitch, 1997; Song
et al., 2004; Coppini et al., 2013; Belardinelli et al., 2013;
Rajamani et al., 2016)].
Ranolazine and GS-458967 has been shown to suppress
dofetilide-induced TdP in a canine in vivo model (Antoons
et al., 2010; Bossu et al., 2018).
There was one experimental study about the potential
antiarrhythmic role of F15845, where it prevented ischemia-
induced arrhythmias in rats (Pignier et al., 2010). However the
use of a rat model makes it hard to extrapolate this study
to humans.
Under the pathological conditions listed above, the fine
balance between the inward and outward currents during the
AP plateau is shifted toward the depolarizing inward currents,
resulting in a longer AP. Therefore, theoretically, any
intervention that reduces the depolarizing currents (e.g.: L-type
calcium current, NCX current, INa,late) could be effective in
bringing the repolarization closer to normal. In this setting,
therefore, inhibiting INa,late will reduce the depolarization drive
resulting in a significantly shorter APD and the suppression of
arrhythmogenic events such as EADs, even if the magnitude of
INa,late is not increased. Under similar conditions, other
interventions such as L-type calcium channel blockade
(Abrahamsson et al., 1996) or potassium channel activation
(Carlsson et al., 1992) can also shorten APD, reduce
repolarization heterogeneity, and suppress the occurrence of
arrhythmogenic events even if INa,late is upregulated. In LQT
syndromes INa,late-mediated increase in Ca
2+
i is just a fraction of
the total Ca2+i, and even total Ca
2+
i just contributes to rather
than determines the arrhythmogenic events (Carlsson
et al., 1996).Tachycardia-Induced Tachyarrhythmias (VT, VF)
INa,late blockers seem to effectively prevent or terminate
tachycardia-induced ventricular tachycardia, and ventricular
fibrillation in healthy animal models in the presence of a b-
adrenergic agonist (Alves Bento et al., 2015; Carneiro et al., 2015;
Bacic et al., 2017).
However, inhibition of INa,late does not likely play a crucial
role here, based on the following theoretical considerations. ToApril 2020 | Volume 11 | Article 413
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is quite small, as it was discussed in Heart Rate and AP Duration
Influences INa,late. Furthermore, at rapid heart rates with b-
adrenergic stimulation the major arrhythmogenic mechanism
is likely to be the increased L-type calcium current, the increased
SR Ca2+ content, and the leaky RyR together (Merchant and
Armoundas, 2012). The third but similarly important factor is
that these VT/VF episodes are likely underlain by a reentry
mechanism, therefore heavily depending on the fast conduction
provided by INa,early. At high pacing rates the “specific” INa,late
inhibitors will also block a considerable amount of INa,early as well
(see Selective INa,late Inhibitors for details), and this might just be
enough to break the reentry circuit (Burashnikov and
Antzelevitch, 2017).
Based on the experimental data, INa,late inhibition seems to be
a valid therapeutic approach to tackle ventricular arrhythmias
especially at low heart rates. These experimental studies also
suggest that INa,late inhibition mainly affects the arrhythmogenic
substrate by making the repolarization less heterogenous
(Carneiro et al., 2015), with only low impact on suppressing
the triggers (Bossu et al., 2018).
Late Sodium Current Inhibition in AF
GS-458967 was shown to suppress isoproterenol-, and high
Ca2+-induced DADs in healthy canine pulmonary-, and
superior vena cava preparations (Sicouri et al., 2013). GS-
458967 also suppressed autonomically triggered AF in an
intact porcine model (Carneiro et al., 2015). In other
experimental studies, “classic” sodium channel inhibitors
(eg, lidocaine, flecainide) also prevented and terminated AF
(Wang et al., 1992; Comtois et al., 2008). However, these
agents were used at concentrations causing a suppression of
INa,early. Experimental data about ranolazine shows an
e ff e c t i v e reduc t ion o f AF burden (AFB) on ly a t
concentrat ions that potent ly inhibi t both INa , e a r l y
(Burashnikov et al., 2007; Kumar et al., 2009; Burashnikov
et al., 2014) and IKr (Burashnikov et al., 2007) Suppressing IKr
reduces the diastolic interval between APs therefore
promoting rate-dependent INa,early inhibition.
Based on these data, specific INa,late blockade alone is not a clear
and straightforward approach in AF, except for cases when a
longer atrial AP is the pathogenetic factor in the initiation of AF.
Clinical Studies
Ranolazine
So far, ranolazine has been used in the vast majority of clinical
studies involving INa,late blockers. When interpreting these trials,
it has to be considered that ranolazine has other effects besides
inhibiting INa,late. With the use of ranolazine, the first favorable
results from phase 2 clinical trials were published in the 1990s
(Cocco et al., 1992; Thadani et al., 1994). In 2006, following the
outcome of the MARISA (Chaitman et al., 2004a), CARISA
(Chaitman et al., 2004b), and ERICA (Stone et al., 2006) trials,Frontiers in Pharmacology | www.frontiersin.org 10the Food and Drug Administration approved ranolazine as an
anti-anginal agent.
The effect of clinical outcome and safety of ranolazine therapy
was investigated in more than 6,500 patients with non-ST-
elevation acute coronary syndrome in the MERLIN TIMI-36
trial (Morrow et al., 2007). Although cardiovascular death or
myocardial infarction has not been significantly reduced by
ranolazine when compared to standard therapy; but recurrent
ischemia (Morrow et al., 2007) and the incidence of arrhythmias
(Scirica et al., 2007) were significantly lower with ranolazine.
Treatment with ranolazine, compared to placebo, resulted in
significantly lower incidences of arrhythmias. Fewer patients had
episodes of ventricular tachycardia lasting more than eight beats
[166 (5.3%) versus 265 (8.3%); p<0.001], supraventricular
tachycardia [1413 (44.7%) versus 1752 (55.0%); p<0.001], or
new-onset AF [55 (1.7%) versus 75 (2.4%); p=0.08]. Moreover,
longer than 3 s pauses were less frequent with ranolazine [97
(3.1%) versus 136 (4.3%); p=0.01].
In the double-blind HARMONY (ClinicalTrials.gov ID:
NCT01522651) phase 2 trial (Reiffel et al., 2015), patients with
paroxysmal AF and implanted pacemakers were enrolled, so that
AFB could continuously be monitored over the 12 weeks of
treatment period. Patients were randomized to placebo,
ranolazine alone (750 mg twice a day—BID), dronedarone
alone (225 mg BID), or ranolazine (750 mg BID) combined
with dronedarone (either 150 mg BID or 225 mg BID). The idea
behind the combination was to reduce the dose of dronedarone,
and therefore the negative inotropic effect associated with
dronedarone. Placebo or the drugs alone did not significantly
reduce AFB. In the combination therapies, however, ranolazine
with dronedarone 225 mg BID reduced AFB by 59% vs placebo
(p=0.008), and ranolazine with dronedarone 150 mg BID
reduced AFB by 43% (p=0.072). Also, patients tolerated both
combinations well.
Into the RAFFAELLO phase 2 trial (De Ferrari et al., 2015)
patients with persistent AF (7 days to 6 months) were enrolled.
Two hours after successful electrical cardioversion participants
were randomized to either placebo, or ranolazine 375 mg, 500
mg, or 750 mg BID. Patients were monitored daily by
transtelephonic ECG. The primary end-point was the time to
first AF recurrence. No dose of the ranolazine prolonged time to
AF recurrence significantly compared to placebo. Of the 238
patients who took at least one dose of the study drug, AF
recurred in 56.4%, 56.9%, 41.7%, and 39.7% of patients in the
placebo and ranolazine 375 mg/500 mg/750 mg groups,
respectively. The reduction in overall AF recurrence in the
combined 500-mg and 750-mg groups was of borderline
significance compared to the placebo group (p=0.053) and
significant compared to 375-mg group (p=0.035).
The RAID clinical trial (NCT01534962) (Zareba et al., 2018)
investigated high-risk cardiomyopathy patients who received an
implantable cardioverter-defibrillator (ICD). The subjects
received either ranolazine (1,000 mg BID) or placebo. The
primary endpoints were VT or VF requiring ICD shock orApril 2020 | Volume 11 | Article 413
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hazard ratio was 0.84 (95% confidence interval: 0.67 to 1.05;
p=0.117) for the primary endpoint. In the ranolazine group the
risk of ICD therapies for recurrent VT or VF were significantly
lower (hazard ratio: 0.70; 95% confidence interval: 0.51 to 0.96;
p=0.028). Other effects of ranolazine treatment however has not
been significant. These included individual components of the
primary endpoint, quality of life, cardiac hospitalizations, and
inappropriate ICD shocks as well.
In a smaller group of participants of the RAND-CFR trial
(NCT01754259) (Evaristo et al., 2018) where symptomatic
diabetic patients participated with non-flow-limiting coronary
artery stenosis with diffuse atherosclerosis and/or microvascular
dysfunction, effect of ranolazine on T-wave heterogeneity was
evaluated. At physical rest, in the ranolazine group T-wave
heterogeneity was 28 % smaller (placebo: 47±6 mV, ranolazine:
39±5 mV, p=0.002), however ranolazine did not differ from the
placebo group during exercise. The trial also suggested that
reduction in repolarization abnormalities seemed to be
independent of alterations in myocardial blood flow.
In a meta-analysis of eight randomized clinical trials (Gong et al.,
2017) Gong et al. found that ranolazine significantly reduced AF
incidence in different clinical settings, such as in acute coronary
syndromes, after cardiac surgery and after electrical cardioversion of
AF (relative risk=0.67, 95% confidence interval: 0.52–0.87, p=0.002).
Moreover, the combined use of ranolazine and amiodarone
compared to amiodarone alone showed a 1.23-times higher
conversion rate of AF (95% confidence interval: 1.08–1.40),
together with a significantly, about 10 h shorter conversion time.
Based on the evidence above, ranolazine may have
therapeutic role in the treatment of cardiac rhythm disorders,
of both atrial and ventricular origin. For stronger evidence, more
phase 3 clinical investigations are necessary.Eleclazine (GS-6615)
Besides ranolazine, until now eleclazine was the only other selective
INa,late inhibitor drug candidate that made it to phase 3 clinical trials.
In the first trial (NCT02300558) eleclazine was tested for safety,
tolerability, and its effect on shortening of the QT interval in LQT3
patients. The primary outcome of the study showed that after 24
weeks the mean daytime corrected QT interval was significantly, 8.5
ms shorter than at baseline, and there was only one patient with a
serious adverse event (nephrolithiasis). The other trial (LIBERTY-
HCM; NCT02291237) targeted HCM patients for the effect of
eleclazine on exercise capacity. In this trial, eleclazine has not
been proven to be superior to placebo.
The last moment in the development of eleclazine came after
results of the phase 2 TEMPO study (NCT02104583) were
analyzed. In the trial, subjects with ventricular tachycardia/
ventricular fibrillation and ICD participated. Results of the
study have shown that the rate of ICD shocks was higher in
subjects who received eleclazine compared to the placebo arm.Frontiers in Pharmacology | www.frontiersin.org 11Therefore in late 2016, the further development of eleclazine was
terminated for all indications.CONCLUSIONS
An increased INa,late is present in many heart diseases. The
upregulated INa,late lengthens the cardiac AP, increases [Na
+]i, and
causes Ca2+ overload of cardiomyocytes by offsetting the forward
mode NCX. The elevated Ca2+, in turn, mainly through CaMKII, can
further increase INa,late in a vicious circle. These pathophysiological
mechanisms together may result in impaired cardiac energetics and
contractile dysfunction of the heart as well as cardiac arrhythmias.
The prolonged AP can serve as a substrate that is prone to rhythm
disorders, whereas Ca2+ overload can be the trigger. INa,late seems to
possess a pathogenetic role especially in AF and in ventricular
arrhythmias occurring under bradycardic conditions.
Multitude of pathophysiology studies have drawn the
consequence that selective INa,late inhibition is a favorable
antiarrhythmic tool in many experimental settings. Despite all
these studies, the one and only drug on the market that
selectively inhibits INa,late is ranolazine, although it significantly
affects other ionic currents as well. Ranolazine has been a safe
and effective antianginal medication since 2006 based on large
randomized studies. Some recent clinical evidence also proves
that ranolazine shows favorable effects in AF and in ventricular
arrhythmias. For stronger evidence, more phase 3 clinical
investigations are necessary. Targeting Nav1.8 with specific
inhibitors is also an interesting novel approach in the future of
antiarrhythmic drug therapy.AUTHOR CONTRIBUTIONS
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